3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Carcinoma, Non-Small-Cell Lung
5
Endometrial Neoplasms
3
Breast Neoplasms
3
Ovarian Neoplasms
2
Non Small Cell Lung Carcinoma NSCLC
2
Neoplasms
2
Neoplasm Metastasis
2
Uterine Cervical Neoplasms
1
Urologic Neoplasms
1
Urogenital Neoplasms
1
Triple Negative Breast Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Sarcopenia
1
Penile Neoplasms
1
Non-Small Cell Lung Cancer With HER2- Mutations
1
Malnutrition
1
Male Urogenital Diseases
1
Lung Neoplasms
1
First-line Advanced NSCLC Patients
1
Fallopian Tube Neoplasms
1
Dysgeusia
1
Carcinoma
1
Interventions
pembrolizumab
5
enfortumab vedotin
3
Gemcitabine
3
dodecyl maltoside
2
Sunitinib
2
Cisplatin
2
zidovudine 5'-monophosphate-mannose-albumin conjugate
1
tucatinib
1
testosterone 17 beta-cypionate
1
temsirolimus
1
relatlimab
1
palbociclib
1
niraparib
1
galactosamine-conjugated serum albumin-conjugated-(rhodamine X)20
1
cabozantinib
1
Valproic Acid
1
Urinary Diversion
1
Trastuzumab
1
Testosterone Propionate
1
Standard of Care
1
Sirolimus
1
Rivaroxaban
1
Ringer's acetate
1
Radiosurgery
1
Radiation Dose Hypofractionation
1
Psychiatric Nursing
1
Practice Guidelines as Topic
1
Physical Therapy Modalities
1
Nivolumab
1
Multiparametric Magnetic Resonance Imaging
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Urologic Neoplasms
×
CP protocol
×
1 year
×
Clear all
NCT06353906
2025-12-08
PRIAM
The Netherlands Cancer Institute
Phase 2
Recruiting
27 enrolled